country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-125132

Copy Link Print Information

Agelastatin A

(Synonyms: (-)-Agelastatin A; AglA)

Agelastatin A ((-)-Agelastatin A; AglA), a tetracyclic alkaloid isolated from the sponge Agelas dendromorpha, induces apoptosis and arrests cells in the G2/M phase of the cell cycle, exhibiting antitumor activity.

For research use only. We do not sell to patients.

CAS No.: 152406-28-5
Formula: C₁₂H₁₃BrN₄O₃
Molecular Weight:341.16

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (278 KB)

Agelastatin A Chemical Structure

CAS No.: 152406-28-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	0.46 μM Compound: 1; AglA	Cytotoxicity against human A431 cells after 48 hrs by crystal violet staining based assay Cytotoxicity against human A431 cells after 48 hrs by crystal violet staining based assay	[PMID: 26951751]
BXPC-3	GI₅₀	0.089 μg/mL Compound: 82	Growth inhibition of human BXPC-3 cells assessed as reduction in cell viability measured after 3 days by CCK-8 assay Growth inhibition of human BXPC-3 cells assessed as reduction in cell viability measured after 3 days by CCK-8 assay	[PMID: 38181652]
DU-145	GI₅₀	0.056 μg/mL Compound: 82	Growth inhibition of human DU-145 cells Growth inhibition of human DU-145 cells	[PMID: 38181652]
DU-145	IC₅₀	2.3 μM Compound: 1, AA, (-)-Agelastatin A	Cytotoxicity against human DU145 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay	10.1039/C3MD00094J
FaDu	GI₅₀	0.24 μg/mL Compound: 82	Growth inhibition of human FaDu cells Growth inhibition of human FaDu cells	[PMID: 38181652]
HeLa	EC₅₀	0.11 μM Compound: 1a	Antitumor activity against human HeLa cells assessed as cell viability by MTT assay Antitumor activity against human HeLa cells assessed as cell viability by MTT assay	[PMID: 24673739]
HeLa	IC₅₀	0.084 μM Compound: 1; AglA	Cytotoxicity against human HeLa cells after 24 hrs by [3H]-thymidine incorporation assay Cytotoxicity against human HeLa cells after 24 hrs by [3H]-thymidine incorporation assay	[PMID: 26951751]
JVM-2	EC₅₀	0.28 μM Compound: 1a	Antitumor activity against human JVM2 cells assessed as cell viability after 48 hrs by FACS analysis Antitumor activity against human JVM2 cells assessed as cell viability after 48 hrs by FACS analysis	[PMID: 24673739]
KB	IC₅₀	0.5 μg/mL Compound: 1a	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 24673739]
KM-20L2	GI₅₀	0.036 μg/mL Compound: 82	Growth inhibition of human KM-20L2 cells Growth inhibition of human KM-20L2 cells	[PMID: 38181652]
MCF7	GI₅₀	0.033 μg/mL Compound: 82	Growth inhibition of human MCF7 cells Growth inhibition of human MCF7 cells	[PMID: 38181652]
NCI-H460	GI₅₀	0.036 μg/mL Compound: 82	Growth inhibition of human NCI-H460 cells Growth inhibition of human NCI-H460 cells	[PMID: 38181652]
P388	ED₅₀	0.052 μg/mL Compound: 82	Anticancer activity against mouse P388 cells assessed as inhibition of cell growth Anticancer activity against mouse P388 cells assessed as inhibition of cell growth	[PMID: 38181652]
Raji	IC₅₀	0.14 μM Compound: 1, AA, (-)-Agelastatin A	Cytotoxicity against human Raji cells assessed as inhibition of cell proliferation after 3 days by coulter counter analysis Cytotoxicity against human Raji cells assessed as inhibition of cell proliferation after 3 days by coulter counter analysis	10.1039/C3MD00094J
SF-268	GI₅₀	0.038 μg/mL Compound: 82	Growth inhibition of human SF-268 cells Growth inhibition of human SF-268 cells	[PMID: 38181652]
SJSA-1	IC₅₀	0.44 μM Compound: 1; AglA	Cytotoxicity against human SJSA1 cells after 48 hrs by crystal violet staining based assay Cytotoxicity against human SJSA1 cells after 48 hrs by crystal violet staining based assay	[PMID: 26951751]
SK-N-SH	GI₅₀	0.042 μg/mL Compound: 82	Growth inhibition of human SK-N-SH cells Growth inhibition of human SK-N-SH cells	[PMID: 38181652]
SW-1736	GI₅₀	0.12 μg/mL Compound: 82	Growth inhibition of human SW-1736 cells Growth inhibition of human SW-1736 cells	[PMID: 38181652]

In Vitro

Agelastatin A(0-2 μM, 48 h) has IC50 values of 67 nM, 708 nM, 1.05 μM, 278 nM and 1.11 μM on U-937, HeLa, A549, BT549 and IMR90 cells, respectively^[1].
Agelastatin A(0-1 μM, 48 h) has IC50 values of 20, 74, 20, 138 and 187 nM on CEM, Jurkat, Daudi, HL-60 and CA46 cells, respectively^[1].
Agelastatin A (0-150 nM, 16 h) can dose-dependently induce U-937 cell cycle arrest at G2/M^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The pharmacokinetic parameters of Agelastatin A(1a) a single 2.5 mg/kg dose in mice^[2].

Parameter/td>	intravenous (IV)	intraperitoneal (IP)
ACU	1742	2946
C_max	4.5 μM	1.65 μM
T_max	2 min	30 min
t_1/2	4 min	1 h

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 152406-28-5
Molecular Weight 341.16
Formula C₁₂H₁₃BrN₄O₃
SMILES

BrC(N1[C@@]2([H])[C@](N3)([H])[C@@]4([H])[C@@](C2)(N(C(N4)=O)C)O)=CC=C1C3=O
Synonyms

(-)-Agelastatin A; AglA
Structure Classification
- Alkaloids
- Other Alkaloids
Initial Source
- Animals
A. dendromorpha
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Sunkyu Han, et al. Synthesis and anticancer activity of all known (-)-agelastatin alkaloids. J Org Chem. 2013 Dec 6;78(23):11970-84. [Content Brief]

[2]. E Paige Stout, et al. Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies. J Med Chem. 2014 Jun 26;57(12):5085-93. doi: 10.1021/jm4016922. Epub 2014 Jun. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote